Prospective study of Eribulin plus Trastuzumab in patients with HER-2 positive metastatic breast cancer (KSCOG-BC06)
Phase 2
- Conditions
- HER2 positive metastatic breast cancer
- Registration Number
- JPRN-UMIN000010761
- Lead Sponsor
- Kurume University School of Medicine Department of Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1.With contraindicate Eribulin and Trastuzumab 2.With active double cancer 3.With uncontrolled diabetes 4.Heart failure with clinically problem 5.Symptomatic brain metastasis 6.With mental disorder which become problem on clinical practice 7.With uncontrolled hypertension 8.Physician judged improper to entry this trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate,Safety
- Secondary Outcome Measures
Name Time Method